Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
P/S ratio for Personalis, Inc. (PSNL)
P/S ratio as of 2023: 1.38
According to Personalis, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.38. At the end of 2022 the company had a P/S ratio of 1.39.
P/S ratio history for Personalis, Inc. from 2017 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 1.38 |
| 2022 | 1.39 |
| 2021 | 7.33 |
| 2020 | 18.20 |
| 2019 | 5.22 |
| 2018 | 16.41 |
| 2017 | 65.98 |